Alessandro Pastore

List of Publications by Year
in descending order

34	4,812	304368 22	476904 29
papers	citations	h-index	g-index

34	34	34	10298
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell, 2015, 163, 506-519.	13.5	1,485
2	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncology, The, 2015, 16, 1111-1122.	5.1	483
3	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery, 2017, 7, 1018-1029.	7.7	302
4	Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine, 2016, 22, 672-678.	15.2	301
5	Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell, 2019, 35, 369-384.e7.	7.7	238
6	Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science, 2019, 366, 1143-1149.	6.0	217
7	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature, 2019, 571, 355-360.	13.7	206
8	Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature, 2019, 569, 576-580.	13.7	195
9	Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell, 2018, 34, 225-241.e8.	7.7	162
10	Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature, 2019, 574, 273-277.	13.7	149
11	A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature, 2017, 549, 389-393.	13.7	144
12	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	15.2	122
13	Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. Journal of Experimental Medicine, 2018, 215, 1729-1747.	4.2	113
14	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	9.4	110
15	KMT2C mediates the estrogen dependence of breast cancer through regulation of ERÎ± enhancer function. Oncogene, 2018, 37, 4692-4710.	2.6	102
16	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell, 2020, 38, 198-211.e8.	7.7	99
17	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature Communications, 2019, 10, 1874.	5.8	63
18	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. Cancer Discovery, 2019, 9, 1452-1467.	7.7	60

#	Article	IF	Citations
19	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications, 2017, 8, 15429.	5.8	55
20	PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN. Cancer Discovery, 2020, 10, 1742-1757.	7.7	55
21	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. Cell Reports, 2020, 31, 107522.	2.9	50
22	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. Blood, 2018, 132, 1695-1702.	0.6	49
23	Impact of age on clinical risk scores in follicular lymphoma. Blood Advances, 2019, 3, 1033-1038.	2.5	18
24	Impact of age on genetics and treatment efficacy in follicular lymphoma. Haematologica, 2018, 103, e364-e367.	1.7	10
25	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. Blood, 2018, 132, 49-49.	0.6	10
26	CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A. Journal of Hematology and Oncology, 2019, 12, 85.	6.9	7
27	PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN. Blood, 2019, 134, 473-473.	0.6	4
28	Targeting MYC-Driven B-Cell Lymphoma By Inhibition of the Histone Methyltransferase DOT1L. Blood, 2018, 132, 2839-2839.	0.6	2
29	High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations. Blood, 2018, 132, 541-541.	0.6	1
30	HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA. Hematological Oncology, 2017, 35, 97-98.	0.8	0
31	Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial. Blood, 2018, 132, 4096-4096.	0.6	0
32	Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms. Blood, 2018, 132, 427-427.	0.6	0
33	Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution. Blood, 2018, 132, 1312-1312.	0.6	0
34	Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma. Blood, 2019, 134, 657-657.	0.6	0